Nonetheless, the observed additive effects in all NB phenotypes in our study suggest that the addition of CHK1 inhibition could potentially be used to lower the required dose of classic chemotherapeutics and thereby limit the toxic side effects that are often associated with these therapies. The gene discussed is CHEK1; the disease is neuroblastoma.